• 1
    Chang SS, Cookson MS. Non-muscle invasive bladder cancer: the role of radical cystectomy. Urology 2005; 66: 91722
  • 2
    Parekh DJ, Bochner BH, Dalbagni G. Superficial and muscle invasive bladder cancer: Principles of management for outcomes assessment. J Clin Oncol 2006; 24: 551927
  • 3
    Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167: 157383
  • 4
    Brake M, Loertzer H, Horsch R, Keller H. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000; 163: 1697701
  • 5
    Pansadoro V, Emiliozzi P, Defidio L et al. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long term results. J Urol 1995; 154: 20548
  • 6
    Bianco FJ Jr, Justa D, Grignon DJ, Sakr WA, Pontes JE, Wood DP Jr. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 2004; 22: 2904
  • 7
    Wiesner C, Pfitzenmaier J, Faldum A, Gillitzer R, Melchior SW, Thüroff JW. Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy. BJU Int 2005; 95: 3015
  • 8
    Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 2001; 166: 4903
  • 9
    Stöckle M, Alken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R. Radical cystectomy – often too late? Eur Urol 1987; 13: 3617
  • 10
    Hautmann RE, Volkmer BG, Gust K. Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3). World J Urol 2009; 27: 34751
  • 11
    Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 2005; 174: 21347
  • 12
    Dalbagni G, Vora K, Kaag M et al. Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1 Bladder Cancer. Eur Urol 2009; 56: 90310
  • 13
    Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001; 166: 12969
  • 14
    Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003; 169: 96100; discussion 100
  • 15
    Orsola A, Trias I, Raventós CX et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. J Urol 2009; 182: 7884; discussion 84.
  • 16
    Shariat SF, Bolenz C, Godoy G et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. Eur Urol 2005; 48: 2318
  • 17
    Chatterjee SJ, Datar R, Youssefzadeh D et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22: 100713